SERA PROGNOSTICS, INC.
SERA · XNASCIK 1534969fmd_1ZSKRVEKKPAM2FCXWNH4PCD43VServices · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | – | – | – | 0 | 0 | 0 |
| Gross profit | – | – | – | 0 | (0) | (0) |
| Research and development | 8 | 11 | 14 | 15 | 15 | 13 |
| Selling, general and administrative | 10 | 24 | 31 | 25 | 22 | 23 |
| Total operating expenses | 18 | 35 | 46 | 40 | 37 | 37 |
| Operating income | (18) | (35) | (46) | (40) | (37) | (37) |
| Interest expense | – | – | – | 0 | 0 | 0 |
| Other non-operating income (expense) | (0) | 1 | 2 | 4 | 4 | 5 |
| Income before taxes | – | – | – | – | (33) | (32) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (33) | (32) |
| Net income | (20) | (35) | (44) | (36) | (33) | (32) |